Cargando…
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
Even though several SARS-CoV-2 vaccines have shown high effectiveness in the prevention of COVID-19 in healthy subjects, vaccination response in patients with plasma-cell-related disorders (PCD) remains widely unknown. Here, we report on an analysis describing the serological response after prime-bo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658197/ https://www.ncbi.nlm.nih.gov/pubmed/34884200 http://dx.doi.org/10.3390/jcm10235499 |
_version_ | 1784612673708621824 |
---|---|
author | Ghandili, Susanne Schönlein, Martin Wiessner, Christian Becher, Heiko Lütgehetmann, Marc Brehm, Thomas Theo Schulze zur Wiesch, Julian Bokemeyer, Carsten Sinn, Marianne Weisel, Katja C. Leypoldt, Lisa B. |
author_facet | Ghandili, Susanne Schönlein, Martin Wiessner, Christian Becher, Heiko Lütgehetmann, Marc Brehm, Thomas Theo Schulze zur Wiesch, Julian Bokemeyer, Carsten Sinn, Marianne Weisel, Katja C. Leypoldt, Lisa B. |
author_sort | Ghandili, Susanne |
collection | PubMed |
description | Even though several SARS-CoV-2 vaccines have shown high effectiveness in the prevention of COVID-19 in healthy subjects, vaccination response in patients with plasma-cell-related disorders (PCD) remains widely unknown. Here, we report on an analysis describing the serological response after prime-boost SARS-CoV-2 vaccination in PCD patients, as compared to a healthy control group, and on possible influencing factors of serological responses. Blood samples were analyzed for the presence of quantitative anti-SARS-CoV-2 spike RBD Ig. A total of 82 patients were included; 67 received mRNA-, eight vector-based and four heterologous vaccinations. SARS-CoV-2 antibody titers (SP-AbT) were assessed in a mean of 23 days (SD ± 11 days) after the first and in a mean 21 days (SD ± 9) after prime-boost vaccination. A positive SP-AbT was detected in 31.9% of PCD patients after the first vaccination, and in 88.9% (44/49) after prime-boost vaccination, which was significantly less likely than that in the control group (100%, 78/78) (p = 0.008). Furthermore, we have been able to validate our previously suggested threshold of 30 CD19+ B lymphocytes/µL as being predictive for SP-AbT development. Despite anti-CD38 directed therapy, quadruplet treatment, higher age and missing deep remission, which correlated negatively with SP-AbT appearance, SP-AbT formation is possible in a majority of myeloma patients after prime-boost vaccination. |
format | Online Article Text |
id | pubmed-8658197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86581972021-12-10 Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma Ghandili, Susanne Schönlein, Martin Wiessner, Christian Becher, Heiko Lütgehetmann, Marc Brehm, Thomas Theo Schulze zur Wiesch, Julian Bokemeyer, Carsten Sinn, Marianne Weisel, Katja C. Leypoldt, Lisa B. J Clin Med Article Even though several SARS-CoV-2 vaccines have shown high effectiveness in the prevention of COVID-19 in healthy subjects, vaccination response in patients with plasma-cell-related disorders (PCD) remains widely unknown. Here, we report on an analysis describing the serological response after prime-boost SARS-CoV-2 vaccination in PCD patients, as compared to a healthy control group, and on possible influencing factors of serological responses. Blood samples were analyzed for the presence of quantitative anti-SARS-CoV-2 spike RBD Ig. A total of 82 patients were included; 67 received mRNA-, eight vector-based and four heterologous vaccinations. SARS-CoV-2 antibody titers (SP-AbT) were assessed in a mean of 23 days (SD ± 11 days) after the first and in a mean 21 days (SD ± 9) after prime-boost vaccination. A positive SP-AbT was detected in 31.9% of PCD patients after the first vaccination, and in 88.9% (44/49) after prime-boost vaccination, which was significantly less likely than that in the control group (100%, 78/78) (p = 0.008). Furthermore, we have been able to validate our previously suggested threshold of 30 CD19+ B lymphocytes/µL as being predictive for SP-AbT development. Despite anti-CD38 directed therapy, quadruplet treatment, higher age and missing deep remission, which correlated negatively with SP-AbT appearance, SP-AbT formation is possible in a majority of myeloma patients after prime-boost vaccination. MDPI 2021-11-24 /pmc/articles/PMC8658197/ /pubmed/34884200 http://dx.doi.org/10.3390/jcm10235499 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ghandili, Susanne Schönlein, Martin Wiessner, Christian Becher, Heiko Lütgehetmann, Marc Brehm, Thomas Theo Schulze zur Wiesch, Julian Bokemeyer, Carsten Sinn, Marianne Weisel, Katja C. Leypoldt, Lisa B. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma |
title | Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma |
title_full | Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma |
title_fullStr | Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma |
title_full_unstemmed | Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma |
title_short | Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma |
title_sort | lymphocytopenia and anti-cd38 directed treatment impact the serological sars-cov-2 response after prime boost vaccination in patients with multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658197/ https://www.ncbi.nlm.nih.gov/pubmed/34884200 http://dx.doi.org/10.3390/jcm10235499 |
work_keys_str_mv | AT ghandilisusanne lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT schonleinmartin lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT wiessnerchristian lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT becherheiko lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT lutgehetmannmarc lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT brehmthomastheo lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT schulzezurwieschjulian lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT bokemeyercarsten lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT sinnmarianne lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT weiselkatjac lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma AT leypoldtlisab lymphocytopeniaandanticd38directedtreatmentimpacttheserologicalsarscov2responseafterprimeboostvaccinationinpatientswithmultiplemyeloma |